"There are three core strengths that separate Third Rock – the experience of its people, the innovation of the science it's pursuing with its portfolio companies and the firm's ability to think big to address some of the most challenging diseases and conditions. Combined, these strengths give Third Rock the capability to help develop new treatments that will have a dramatic and significant impact on patients' lives."
Eleven Biotherapeutics September 20, 2013 - Eleven Biotherapeutics Presents Positive Clinical Data on EBI-005, a Targeted Protein Therapeutic for Highly Selective Topical Blockade of IL-1 in Patients with Dry Eye Disease » Press Release | Company News
Rhythm September 10, 2013 - Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease » Press Release | Company News
Constellation Pharmaceuticals September 10, 2013 - Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma